IP Library Granted Patent US 10,874,728
Granted Patent B2
US 10,874,728 · App. 15/075,451 · Granted Dec 29, 2020

Tumor vascular marker-targeted vaccines

Inventors: George Coukos (Wynnewood, PA); Andrea Facciabene (Philadelphia, PA)
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
A61K39/0011A61K41/0057A61K48/00A61K51/1045C07H21/04C07K14/4748C07K16/2851A61K2039/53A61K2039/55516A61K2039/58A61K2039/62C07K2317/24C07K2319/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,874,728
App. No.
15/075,451
Granted
Dec 29, 2020
Kind
B2
Abstract

The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.

Claims (7)

1. A method of inhibiting the growth of, suppressing the growth of, decreasing the incidence, and/or recurrence of a tumor in a subject, wherein the vasculature supplying said tumor comprises a tumor endothelial marker (TEM-1) protein, comprising the steps of:

a. identifying expression of said TEM-1 by said tumor by contacting said subject with a labeled compound that binds said TEM-1 or a nucleic acid molecule encoding said TEM-1;

b. detecting said label;

c. contacting said subject with an antibody to said TEM-1, wherein said antibody is labeled with a radionuclide to deliver cytotoxic radiation to tumor vasculature expressing said TEM-1; and

d. contacting said subject with a polypeptide comprising said TEM-1 protein or an immunogenic fragment thereof comprising an extracellular domain of TEM-1, said TEM-1 protein or said immunogenic fragment thereof fused to the N-terminal domain of fragment C of tetanus toxoid (DOM), or with a nucleic acid construct encoding said TEM-1 protein or said immunogenic fragment thereof, said nucleic acid fused in frame to a nucleic acid sequence encoding the N-terminal domain of fragment C of tetanus toxoid (DOM), to induce an immune response against said TEM-1.

2. The method of claim 1 , wherein said detecting step is performed using positron emission tomography (PET) scanning.

3. The method of claim 2 , wherein said detecting step also utilizes computed tomography (CT) or magnetic resonance imaging (MRI) scanning.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2018
From: COUKOS, GEORGE; FACCIABENE, ANDREA
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 045065/0690 →
CONFIRMATORY LICENSE Recorded Sep 19, 2016
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040069/0053 →
Continuity (4)
Division 13121638 · Aug 25, 2011
Provisional Application 61101083 · Sep 29, 2008
Provisional Application 61181659 · May 27, 2009
Related Publication 20160331819A1 · Nov 17, 2016